EMBARGOED: CAR-T not cost-effective as second-line therapy for diffuse large B-cell lymphoma at current prices, study finds
EMBARGOED: December 4, 2023, 5PM EST Contact: Nicole Oliverio, Dana-Farber Cancer Institute 617-257-0454, nicole_oliverio@dfci.harvard.edu CAR-T not cost-effective as second-line therapy ...